ESKD

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, March 12, 2024
Administration, Plasma, Kidney disease, ECTS, Massachusetts General Hospital, Pyrophosphate, PD, ASN, Partnership, Pharmacokinetics, Calciphylaxis, G&A, PROPEL, Doctor of Philosophy, Chemistry, Investment, PXE, Society, Pathology, Therapy, Safety, Research and development, ESKD, ENPP1, MMSc, Natural history, Pharmaceutical industry

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “We believe we are well-positioned to continue to advance INZ-701 through several anticipated value-creating milestones in the year ahead,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • Calciphylaxis represents a devastating condition characterized by pathologic mineralization and intimal proliferation.
  • Patients will receive 1.8 mg/kg of INZ-701 once weekly, coinciding with their hemodialysis treatment, for a total of 30 days.
  • The study’s primary endpoint will assess safety and change from baseline plasma PPi concentration, with secondary endpoints including PK and PD parameters.

Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Retrieved on: 
Friday, March 29, 2024
ODD, Diagnosis, Kidney disease, Prevalence, Kidney, Renal replacement therapy, Patient, Orphan, ESKD, FDA, Pharmaceutical industry

"We are very excited that AP303 has been granted Orphan Drug Designation by the FDA", Dr. Gavin Xia, Co-founder, Chairman, and CEO of Alebund commented.

Key Points: 
  • "We are very excited that AP303 has been granted Orphan Drug Designation by the FDA", Dr. Gavin Xia, Co-founder, Chairman, and CEO of Alebund commented.
  • "It is an important milestone for Alebund as well as our efforts to address the significant unmet medical needs with ADPKD.
  • AP303, a novel drug candidate developed in-house by Alebund, has demonstrated a meaningful improvement of renal survival in an ADPKD mice model.
  • This Orphan Drug Designation reflects the need for more new treatment options and the potential for AP303 to address the pressing needs of people living with ADPKD.

Panoramic Health and The Kidney and Hypertension Center Join Forces to Elevate Kidney Care in Ohio

Retrieved on: 
Tuesday, March 19, 2024
Kidney, Health, Kidney disease, Growth, KHC, Partnership, CKD, Patient, Investment, Panorama, Chronic kidney disease, ESKD, Physician, Pharmaceutical industry

TEMPE, Ariz., March 19, 2024 /PRNewswire/ -- Panoramic Health, kidney care's leading integrated provider group, is proud to announce its strategic partnership with The Kidney and Hypertension Center (KHC), the largest independent nephrology practice in Cincinnati, Ohio. This represents the first Panoramic Health integrated provider group partnership in Ohio.

Key Points: 
  • This represents the first Panoramic Health integrated provider group partnership in Ohio.
  • The alliance between Panoramic Health and KHC underscores both entities' dedication to serving the full continuum for patients and physicians through complementary, integrated service lines.
  • "We are thrilled to partner with The Kidney and Hypertension Center in Cincinnati and mark this exciting entry into Ohio," said Dr. Tarek Elsawy, Chief Executive Officer at Panoramic Health.
  • In addition, by leveraging Panoramic Health's value-based care platform, KHC taps into care management that keeps the nephrologist at the center of care delivery, leading to improved patient outcomes.

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Retrieved on: 
Thursday, February 8, 2024
Principal, Kidney disease, Corporate development, Ventricular fibrillation, Therapy, OTC, University, Vitamin K antagonist, Financial management, Antiphospholipid syndrome, ESKD, Patient, Atrial fibrillation, APS, PwC, Intellectual property, VKA, Management

In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin.

Key Points: 
  • In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin.
  • Mr. Cole brings over 25 years of experience in global pharmaceutical manufacturing and commercial operations, finance, and corporate development to the Company.
  • His experience will serve Cadrenal well as we advance our tecarfarin clinical program and evaluate partnering opportunities," commented Quang Pham, Founder, Chairman and Chief Executive Officer of Cadrenal Therapeutics.
  • "I look forward to leveraging my experience to advance tecarfarin to the market and help those underserved patient groups."

Point32Health and Monogram Health Expand Collaboration Aimed at Improving Chronic Kidney Care

Retrieved on: 
Tuesday, January 16, 2024
Patient, African Americans, MD, Health, Tufts Health Plan, Kidney disease, Monogram, Quality of life, Harvard Pilgrim Health Care, Chronic kidney disease, CKD, ESKD, Nursing

and NASHVILLE, Tenn., Jan. 16, 2024 /PRNewswire/ -- Point32Health , the parent company of Tufts Health Plan and Harvard Pilgrim Health Care, today announced an expansion of its relationship with Monogram Health , the nation's leading value-based provider of in-home, evidence-based care and benefit management services for patients living with chronic kidney and end stage kidney disease to include members in its Tufts Health Direct population.

Key Points: 
  • and NASHVILLE, Tenn., Jan. 16, 2024 /PRNewswire/ -- Point32Health , the parent company of Tufts Health Plan and Harvard Pilgrim Health Care, today announced an expansion of its relationship with Monogram Health , the nation's leading value-based provider of in-home, evidence-based care and benefit management services for patients living with chronic kidney and end stage kidney disease to include members in its Tufts Health Direct population.
  • Point32Health and Monogram began working together in 2022 to improve early access to kidney care for Harvard Pilgrim Health Care and Tufts Health commercial members.
  • Through the expanded collaboration, Monogram Health will assume full financial risk for Tufts Health Direct members with kidney disease, delivering industry-leading in-home specialty care services, promoting better patient outcomes while improving affordability.
  • "This powerful collaboration with Point32Health expands Monogram's ability to transform health care for CKD and ESKD patients in the commercial space," said Aash Shah, MD, chief growth officer of Monogram Health.

Alio Announces Expansion of Operations in GCC Market to the UAE Through Partnership with GulfDrug

Retrieved on: 
Monday, January 8, 2024
Kingdom, Auscultation, Partnership, KSA, FDA, Kidney disease, ESKD, Patient, Calibration, Hematocrit, Gulf Cooperation Council, GCC, Medical device

BROOMFIELD, Colo., Jan. 8, 2024 /PRNewswire/ -- Today, Alio, Inc. announces its strategic partnership with GulfDrug, one of the top medical suppliers in the United Arab Emirates (UAE). Announcement of this partnership further expands Alio's presence in the Gulf Cooperation Council (GCC), which includes the Kingdom of Saudi Arabia (KSA) and now the UAE. GulfDrug works with best-in-class global companies, like Alio, to distribute a variety of products including pharmaceuticals, surgical tools, and medical equipment. GulfDrug serves a majority of the country's End-Stage Kidney Disease (ESKD) population and intends to distribute the Alio SmartPatch to their 2,200 ESKD patients.

Key Points: 
  • announces its strategic partnership with GulfDrug , one of the top medical suppliers in the United Arab Emirates (UAE).
  • Announcement of this partnership further expands Alio's presence in the Gulf Cooperation Council (GCC), which includes the Kingdom of Saudi Arabia (KSA) and now the UAE.
  • GulfDrug works with best-in-class global companies, like Alio, to distribute a variety of products including pharmaceuticals, surgical tools, and medical equipment.
  • GulfDrug serves a majority of the country's End-Stage Kidney Disease (ESKD) population and intends to distribute the Alio SmartPatch to their 2,200 ESKD patients.

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Assistive technology, Conference, NASDAQ Biotechnology Index, Anticoagulant, Partnership, Metabolism, Risk, Death, Biotechnology, Warfarin, Bleeding, Antiphospholipid syndrome, APS, Atrial fibrillation, Phạm, Therapy, ESKD, Stroke, Splenic infarction, Kidney disease, Ventricular fibrillation, Patient, Apixaban, Pharmaceutical industry

"Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."

Key Points: 
  • "Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."
  • To arrange a meeting with management, please contact your Biotech Showcase representative or Lytham Partners at [email protected] .
  • The ceremony will feature healthcare companies within the Nasdaq Biotechnology Index, highlighting them as companies pioneering the future.
  • The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment

Retrieved on: 
Friday, November 10, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, OAC, International Society, Safety, ESKD, Executive Committee, Risk, Thrombosis, Patient, Atrial fibrillation, Stroke, Bleeding, Trial of the century, Kidney disease, Physician, Pharmaceutical industry, Birth control, ISTH, Hemostasis, Medicine, Bayer

Bayer today announced it expanded its Phase III OCEANIC clinical development program for the investigational drug asundexian (BAY2433334) by initiating a third clinical study, OCEANIC-AFINA.

Key Points: 
  • Bayer today announced it expanded its Phase III OCEANIC clinical development program for the investigational drug asundexian (BAY2433334) by initiating a third clinical study, OCEANIC-AFINA.
  • OCEANIC AFINA is a Phase III study investigating asundexian as a potential treatment option in patients (≥65 years of age) with atrial fibrillation (AF) at high risk for stroke or systemic embolism who are deemed ineligible for oral anticoagulation (OAC) treatment due to an increased risk of bleeding.
  • OCEANIC-AFINA complements OCEANIC-AF, an ongoing Phase III study investigating the efficacy and safety of asundexian for the prevention of stroke or systemic embolism in people with AF.
  • “It is our vision to support patients with atrial fibrillation, including those, that up to now were deemed as not eligible for treatment with OACs.

Kidneylink Announces Program Growth in Value-Based Kidney Care

Retrieved on: 
Wednesday, December 13, 2023
NPS, Chronic kidney disease, Kidney disease, Associate, ESKD, Pharmacist, Risk, RNS, Patient, Nephrology, USRC, Dialysis, CKD, Kidney transplantation, MD, Partnership, Social, Growth, Physician, FASN, Quality of life, Hospital, HIV disease progression rates, Pharmaceutical industry, Nursing

PLANO, Texas, Dec. 13, 2023 /PRNewswire/ -- Kidneylink – a national, value-based kidney care company founded by U.S. Renal Care, is pleased to announce significant growth and success on behalf of its patients and providers – expanding its network to more than 600 nephrologists across 20 U.S. based markets and caring for more than 16,000 people living with kidney disease, both Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD). Since its inception in 2021, Kidneylink has improved clinical outcomes for patients resulting in double-digit percentage reductions in hospitalizations and medical costs.

Key Points: 
  • PLANO, Texas, Dec. 13, 2023 /PRNewswire/ -- Kidneylink – a national, value-based kidney care company founded by U.S. Renal Care , is pleased to announce significant growth and success on behalf of its patients and providers – expanding its network to more than 600 nephrologists across 20 U.S. based markets and caring for more than 16,000 people living with kidney disease, both Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD).
  • Kidneylink is also not limited to U.S. Renal Care dialysis centers—more than 50% of Kidneylink ESKD patients are treated outside of USRC's facilities.
  • Many value-based kidney organizations rely on virtual care management teams that work around the nephrologist.
  • The future of kidney care is value-based care.

Alio Officially Enters GCC Market Through Partnership with Al Redwan

Retrieved on: 
Tuesday, December 5, 2023
Calibration, Vascular occlusion, Chronic kidney disease, ESKD, Potassium, Kidney disease, Patient, Dialysis, Kidney, FDA, Hematocrit, Auscultation, Blood, Partnership, Death, Hospital, Quality of life, Health, Alió, Kingdom

BROOMFIELD, Colo., Dec. 5, 2023 /PRNewswire/ -- Today, Alio, Inc. announces its strategic partnership with Al Redwan Medical Services Company, a leader in dialysis and medical lab trading and medical services in the Gulf region. Alio, already commercially available in the United States, has expanded its global presence to the Kingdom of Saudi Arabia to reach a greater number of kidney patients in need.

Key Points: 
  • The Alio Platform dramatically improves the technology solutions available to clinicians by delivering actionable, clinical-grade metrics and notifications at key intervention points.
  • Alio's partnership with Al Redwan allows Alio to manage the more than 3,000 End-Stage Kidney Disease (ESKD) patients for whom Al Redwan directly provides dialysis.
  • Beyond the patients already under Al Redwan's care, the partnership will also enable and facilitate the distribution of Alio products to other hospitals, providers, and partners in the region, including Diaverum.
  • Unfortunately, the technology available to date has only catered to one or two of their conditions," said Mr. Yousef Al Redwan, CEO of Al Redwan Medical Services.